Roles of MiR-101 and its target gene cox-2 in early diagnosis of cervical cancer in uygur women

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 45-48

  Lin, Chen ^a   Huang, Fei ^a   Zhang, Ya Jing ^a   Tuokan, Talafu ^a   Kuerban, Gulinaer ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Cervical cancer; Cox 2; MicroRNA; MiR 101; Uygur ethnicity

Indexed keywords

CYCLOOXYGENASE 2; MICRORNA; MIRN101 MICRORNA, HUMAN; TRANSCRIPTOME; TUMOR MARKER;

ARTICLE; CARCINOMA; CASE CONTROL STUDY; CHEMISTRY; CHINA; EARLY DIAGNOSIS; FEMALE; GENETICS; HUMAN; UTERINE CERVIX TUMOR;

CARCINOMA; CASE-CONTROL STUDIES; CHINA; CYCLOOXYGENASE 2; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MICRORNAS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84894097845     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.45     Document Type: Article

References (20)

1. Arbyn M, Castellsague X, de Sanjose S, et al (2011). Worldwide burden of cervical cancer in 2008. Ann Oncol, 22, 2675-86.
2. Bartel DP (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-33.
3. Bumgarner SL, Dowell RD, Grisafi P, et al (2009). Toggle involving cis-interfering noncoding RNAs controls variegated gene expreassion in yeast. Proc Natl Acad Sci USA, 106, 18321-6.
4. Cao W, Ribeiro Rde O, Liu D, et al (2012). EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS One, 7, e52984.
5. Chandramouli A, Onyeagucha BC, Mercado-Pimentel ME, et al (2012). MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther, 13, 175-83.
6. Chen J, Yao D, Li Y (2013). Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervicalsquamous cell carcinoma. Int J Mol Med, 32, 557-67.
7. Garzon R, Calin GA, Croce CM (2009). MicroRNAs in Cancer. Annu Rev Med, 60, 167-79.
8. Hao Y, Gu X, Zhao Y (2011) Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the Cox-2 pathway in vivo. Cancer Prev Res, 4, 1073-83.
9. Lalaisuzuke, Peng YH, Zhou K, et al (2006). The analysis of pathogenetic tendency of cervical cancer in various ethnic women in Xinjiang. J Xinjiang Med Univ, 29, 569-71.
10. Lee JW, Choi CH, Choi JJ (2008). Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res, 14, 2535-42.
11. Pang Y, Young CY, Yuan H (2010). MicroRNAs and prostate cancer. Acta Biochem Biophys Sin, 42, 363-9.
12. Rao Q, Shen Q, Zhou H, et al.Aberrant microRNA expression in human cervical carcinomas. Med Oncol, 29, 1242-8.
13. Strillacci A, Valerii MC, Sansone P (2013) Loss of miR-101 expression promotes Wnt/β-catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol, 229, 379-89.
14. Su H, Yang JR, Xu T, et al (2009). MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res, 69, 1135-42.
15. Wang HJ, Ruan HJ, He XJ, et al (2010). MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer, 46, 2295-303.
16. Wang R, Wang HB, Hao CJ, et al (2012). MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1. PLoS One, 7, e46173.
17. Wu ZL, Zheng SS, Li ZM, et al (2010). Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ, 17, 801-10.
18. Zhang JG, Guo JF, Liu DL, et al (2011). MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol, 6, 671-8.
19. Zhang Y, Guo X, Xiong L, et al (2012). MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett, 586, 4362-70.
20. Hao Y, Gu X , Zhao Y, et al (2011). Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the Cox-2 pathway in vivo. Cancer Prev Res, 4, 1073-83.